Medication Guide App

Generic Atrovent HFA Availability

Atrovent HFA is a brand name of ipratropium, approved by the FDA in the following formulation(s):

ATROVENT HFA (ipratropium bromide - aerosol, metered;inhalation)

Has a generic version of Atrovent HFA been approved?

No. There is currently no therapeutically equivalent version of Atrovent HFA available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atrovent HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Stabilized medicinal aerosol solution formulations
    Patent 5,676,930
    Issued: October 14, 1997
    Inventor(s): Jager; Paul Donald & Kontny; Mark James & Nagel; Jurgen Hubert
    Assignee(s): Boehringer Ingelheim Pharmaceuticals, Inc.
    Stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide or fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either an inorganic acid or an organic acid are described. The acids are present in amounts sufficient to reduce the degradation of the medicaments to acceptable levels.
    Patent expiration dates:
    • October 14, 2014
      ✓ 
      Drug product
  • Medicinal aerosol formulations
    Patent 5,683,677
    Issued: November 4, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:
    • November 4, 2014
      ✓ 
      Drug product
  • Stainless steel canister for propellant-driven metering aerosols
    Patent 6,739,333
    Issued: May 25, 2004
    Inventor(s): Hubert; Hoelz & Richard Thomas; Lostritto & Juergen; Nagel & Julio César; Vega
    Assignee(s): Boehringer Ingelheim Pharma KG
    The present invention relates to corrosion resistant stainless steel canisters for propellant-containing aerosol forumlations for use in propellant gas-operated inhalers.
    Patent expiration dates:
    • May 26, 2020
      ✓ 
      Drug product
  • Stainless steel canister for propellant-driven metering aerosols
    Patent 6,983,743
    Issued: January 10, 2006
    Inventor(s): Hoelz; Hubert & Lostritto; Richard Thomas & Nagel; Juergen & Vega; Julio César
    Assignee(s): Boehringer Ingelheim Pharma KG
    The present invention relates to corrosion resistant stainless steel canisters for propellant-containing aerosol formulations for use in propellant gas-operated inhalers.
    Patent expiration dates:
    • May 26, 2020
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)